$MDT (Medtronic plc)

$MDT {{ '2015-07-07T15:16:02+0000' | timeago}} • SEC

$MDT FY15 10-K: At FY15-end: Total assets were $106,685MM, up 181.17% from $37,943MM at FY14-end. Total liabilities were $53,455MM, up 188.95% from $18,500MM at FY14-end. Total current assets were $30,844MM, up 45.42% from $21,210MM at FY14-end. Total current liabilities were $9,173MM, up 65.01% from $5,559MM at FY14-end.

$LIVN {{ '2017-07-12T12:45:32+0000' | timeago}} • Announcement

$LIVN appointed Keyna Skeffington as SVP and General Counsel. Skeffington most recently served as Vice President of Legal – Corporate and Securities, Deputy General Counsel and Assistant Secretary at $MDT.

$MDT {{ '2017-07-10T15:43:07+0000' | timeago}} • Announcement

$MDT announced the expanded FDA approval of the self-expanding CoreValve Evolut transcatheter aortic valve replacement platform to include patients with symptomatic severe aortic stenosis who are at an intermediate risk for open-heart surgery.

$MDT {{ '2017-06-23T12:04:14+0000' | timeago}} • Announcement

$MDT has announced a 7% increase in its quarterly cash dividend, raising the amount to $0.46 per ordinary share. The dividend is payable on July 26, 2017, to shareholders of record as of July 7, 2017.

$MDT {{ '2017-06-20T13:54:51+0000' | timeago}} • Announcement

$MDT said data from a recent study showed that its cardiac resynchronization therapy devices reduced healthcare system costs and improved therapy delivery in heart failure patients. A European health-economic analysis indicated that Medtronic’s AdaptivCRT extended life expectancy of patients by about four months, while lowering healthcare costs.

$MDT {{ '2017-06-19T11:01:15+0000' | timeago}} • Announcement

$MDT said its Reactive ATP therapy slows the progression of atrial fibrillation (AF) in patients with implanted cardiac devices. A robust, real-world analysis of nearly 8,800 patients was presented as a late breaking clinical trial at EHRA Europace-Cardiostim 2017.

$MDT {{ '2017-05-25T14:14:38+0000' | timeago}} • Infographic

$MDT Medtronic Plc. Earnings AlphaGraphics: Q4 2017 highlights

$MDT {{ '2017-05-25T12:41:07+0000' | timeago}} • Webcast

$MDT expects FY18 to have operating margin improvement, with greater strength in 2H18. GM on a constant currency basis is expected to be flat to slightly improve throughout FY18, with modest pricing pressure offset by operating improvement. $MDT also expects currency to negatively affect GM in 1H18, with a greater impact in 1Q18 than in 2Q18.

$MDT {{ '2017-05-25T12:37:30+0000' | timeago}} • Webcast

For FY18, $MDT expects Cardiac & Vascular Group to grow in the range of 5-6%, Minimally Invasive Therapies Group to grow in the range of 3-4%, Restorative Therapies Group to grow approx. 4% and Diabetes to grow in the 10-12% range. Additionally, total $MDT revenue growth is expected to be similar to the annual range.

$MDT {{ '2017-05-25T12:20:51+0000' | timeago}} • Webcast

Geographically, $MDT reported balanced performance in 4Q17, with mid single digit growth in the US and non-US developed markets. The company also reported double digit growth in emerging markets.

$MDT {{ '2017-05-25T12:16:50+0000' | timeago}} • Webcast

$MDT stated that the integration of Covidien progressed as planned and the company has realized over $600MM in synergy savings in FY17. The company is also on track to deliver the goal of $850MM of total cost savings by the end of FY18.

$MDT {{ '2017-05-25T11:22:16+0000' | timeago}} • Announcement

In FY18, $MDT expects constant currency revenue growth to be in the range of 4% to 5%. Medtronic sees full-year non-GAAP diluted EPS to grow by 9-10%. Fiscal year guidance does not include the impact of the divestiture of a portion of its Patient Monitoring and Recovery division to $CAH, expected to close in 2Q18.

$MDT {{ '2017-05-25T11:17:39+0000' | timeago}} • Announcement

$MDT's Cardiac and Vascular Group (CVG) worldwide 4Q17 revenue rose 4% to $2.8Bil, while Minimally Invasive Therapies Group (MITG) revenue jumped 6% to $2.6Bil. Restorative Therapies Group (RTG) revenue was about $2.0Bil, up 4%. Diabetes Group worldwide revenue of $512MM increased 3% in the fourth quarter.

$MDT {{ '2017-05-25T11:16:52+0000' | timeago}} • Announcement

$MDT's revenue in 4Q17 grew 5% to $7.9Bil, with net income improving to about $1.2Bil from $1.1Bil. Earnings rose to $0.84 per diluted share from last year's $0.78 a share, as all segments saw revenue bumps in the quarter.

$MDT {{ '2017-05-24T16:36:36+0000' | timeago}} • Announcement

$MDT said the first patient has been enrolled in the IN.PACT AV Access Drug-Coated Balloon study for use in patients with end-stage renal disease. The U.S. Food and Drug Administration approved the study to evaluate safety and efficacy of IN.PACT AV Access DCB as a treatment for failing arteriovenous fistulas in ESRD patients.

$MDT {{ '2017-05-15T15:21:22+0000' | timeago}} • Announcement

$MDT announced new data supporting the clinical performance of its exclusive EffectivCRT Diagnostic and AdaptivCRT algorithm in heart failure patients who receive cardiac resynchronization therapy (CRT) devices. CRT is established treatment that uses implantable defibrillator or pacemaker to improve pumping efficiency of heart.

$MDT {{ '2017-05-11T14:18:04+0000' | timeago}} • Announcement

$MDT said new study reinforced safety and performance of the world's smallest pacemaker in a real-world patient population. The HRS late-breaking trial revealed high implant success rate and low early major complication rate for the $MDT Micra Transcatheter Pacing System.

$MDT {{ '2017-04-26T16:15:43+0000' | timeago}} • Announcement

$MDT reported its Endurant II abdominal aortic aneurysm (AAA) stent graft system continues to demonstrate long-term durability and consistent outcomes in a real-world setting. The 5-year Engage global registry data were presented for the first time at the 2017 Charing Cross Symposium in London.

$MDT {{ '2017-04-25T15:48:56+0000' | timeago}} • Announcement

$MDT announced 3-year outcomes from the VeClose U.S. pivotal clinical trial and one-year data from the WAVES study. The new data demonstrate the clinical and quality of life benefits of the Medtronic VenaSeal closure system in treating patients with venous reflux disease.

$MDT {{ '2017-04-25T13:15:01+0000' | timeago}} • Announcement

$MDT reinforced consistent results for its IN.PACT Admiral drug-coated balloon (DCB) with two new sub-analyses from the IN.PACT Global Study in patients with peripheral artery disease (PAD).

$CAH {{ '2017-04-18T12:35:44+0000' | timeago}} • Announcement

$CAH expects the $MDT portfolio acquisition to be accretive to adjusted diluted EPS by more than $0.55 per share in FY19, and increasingly accretive thereafter. By the end of FY20, the company assumes synergies will exceed $150MM annually.

Recent Transcripts

MSFT (Microsoft Corporation)
Thursday, July 20 2017 - 9:30pm
ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
ELMD (Electromed, Inc.)
Tuesday, May 16 2017 - 1:00pm
VCEL (Vericel Corporation)
Wednesday, May 10 2017 - 12:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
RMTI (Rockwell Medical, Inc.)
Tuesday, May 9 2017 - 8:30pm
NXTM (Nxstage Medical, Inc.)
Tuesday, May 9 2017 - 1:00pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
IRIX (IRIDEX Corporation)
Wednesday, May 3 2017 - 9:30pm
NVDQ (Novadaq Technologies Inc.)
Wednesday, May 3 2017 - 8:30pm
MASI (Masimo Corporation)
Wednesday, May 3 2017 - 8:30pm
LIVN (LivaNova PLC)
Wednesday, May 3 2017 - 1:00pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
ROP (Roper Technologies, Inc.)
Friday, April 28 2017 - 12:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, April 28 2017 - 12:30pm
MSFT (Microsoft Corporation)
Thursday, April 27 2017 - 9:30pm

AlphaGraphics you may like